Liquidia Corp
LQDA34.490USD
+0.060+0.17%
Close 12/31, 16:00（ET）Quotes delayed by 15 min
2.99BMarket Cap
LossP/E TTM
More Details of Liquidia Corp Company
Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
Liquidia Corp Info
Ticker SymbolLQDA
Company nameLiquidia Corp
IPO dateJul 26, 2018
CEOJeffs (Roger A)
Number of employees157
Security typeOrdinary Share
Fiscal year-endJul 26
Address419 Davis Drive
CityMORRISVILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code27560
Phone19193284400
Websitehttps://www.liquidia.com/
Ticker SymbolLQDA
IPO dateJul 26, 2018
CEOJeffs (Roger A)
Company Executives of Liquidia Corp
Name
Name/Position
Position
Shareholding
Change
Dr. Roger A. Jeffs, Ph.D.
Dr. Roger A. Jeffs, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
2.11M
-0.30%
Mr. Russell Schundler, J.D.
Mr. Russell Schundler, J.D.
General Counsel, Secretary
General Counsel, Secretary
367.11K
-0.29%
Mr. Rajeev Saggar, M.D.
Mr. Rajeev Saggar, M.D.
Chief Medical Officer
Chief Medical Officer
169.42K
-29.64%
Mr. Scott Moomaw
Mr. Scott Moomaw
Chief Commercial Officer
Chief Commercial Officer
144.82K
-0.57%
Mr. Jason Adair
Mr. Jason Adair
Chief Business Officer
Chief Business Officer
143.22K
-0.48%
Mr. Michael Kaseta
Mr. Michael Kaseta
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
87.16K
-1.32%
Mr. Damian Degoa
Mr. Damian Degoa
Independent Director
Independent Director
66.11K
+38.55%
Mr. Arthur S. Kirsch
Mr. Arthur S. Kirsch
Independent Director
Independent Director
50.40K
+57.49%
Ms. Katherine (Katie) Rielly-Gauvin
Ms. Katherine (Katie) Rielly-Gauvin
Independent Director
Independent Director
18.40K
--
Dr. Joanna C. Horobin
Dr. Joanna C. Horobin
Independent Director
Independent Director
13.40K
-27.18%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Roger A. Jeffs, Ph.D.
Dr. Roger A. Jeffs, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
2.11M
-0.30%
Mr. Russell Schundler, J.D.
Mr. Russell Schundler, J.D.
General Counsel, Secretary
General Counsel, Secretary
367.11K
-0.29%
Mr. Rajeev Saggar, M.D.
Mr. Rajeev Saggar, M.D.
Chief Medical Officer
Chief Medical Officer
169.42K
-29.64%
Mr. Scott Moomaw
Mr. Scott Moomaw
Chief Commercial Officer
Chief Commercial Officer
144.82K
-0.57%
Mr. Jason Adair
Mr. Jason Adair
Chief Business Officer
Chief Business Officer
143.22K
-0.48%
Mr. Michael Kaseta
Mr. Michael Kaseta
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
87.16K
-1.32%
Revenue Breakdown
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
14.00M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Farallon Capital Management, L.L.C.
9.85%
Caligan Partners, LP
9.33%
Manning (Paul B.)
7.09%
BlackRock Institutional Trust Company, N.A.
5.25%
The Vanguard Group, Inc.
4.54%
Other
63.95%
Shareholders
Shareholders
Proportion
Farallon Capital Management, L.L.C.
9.85%
Caligan Partners, LP
9.33%
Manning (Paul B.)
7.09%
BlackRock Institutional Trust Company, N.A.
5.25%
The Vanguard Group, Inc.
4.54%
Other
63.95%
Shareholder Types
Shareholders
Proportion
Hedge Fund
35.74%
Investment Advisor
18.71%
Individual Investor
11.15%
Investment Advisor/Hedge Fund
10.47%
Research Firm
6.73%
Corporation
2.64%
Family Office
1.88%
Private Equity
0.74%
Bank and Trust
0.45%
Other
11.50%
Institutional Shareholding
Updated: an hour ago
Updated: an hour ago
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
372
63.78M
73.31%
-1.39M
2025Q3
358
61.00M
70.12%
+1.28M
2025Q2
350
67.92M
79.46%
-5.32M
2025Q1
356
67.75M
79.47%
-4.91M
2024Q4
344
63.62M
75.17%
-10.09M
2024Q3
335
73.31M
89.39%
+16.42M
2024Q2
318
66.67M
87.88%
+4.98M
2024Q1
302
59.34M
79.61%
+7.64M
2023Q4
256
48.15M
70.41%
+4.56M
2023Q3
236
40.52M
62.49%
-5.87M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Farallon Capital Management, L.L.C.
6.83M
7.94%
+2.59M
+61.19%
Jul 07, 2025
Caligan Partners, LP
8.12M
9.43%
+300.00
+0.00%
Jun 30, 2025
Manning (Paul B.)
6.16M
7.21%
+18.40K
+0.30%
Jun 17, 2025
BlackRock Institutional Trust Company, N.A.
4.26M
4.95%
+65.79K
+1.57%
Jun 30, 2025
The Vanguard Group, Inc.
3.58M
4.16%
+126.92K
+3.68%
Jun 30, 2025
Findell Capital Management LLC
3.00M
3.48%
+110.00K
+3.81%
Jun 30, 2025
Goldman Sachs & Company, Inc.
2.34M
2.72%
+1.56M
+200.35%
Jun 30, 2025
Opaleye Management Inc.
2.48M
2.87%
+215.00K
+9.51%
Jun 30, 2025
Jeffs (Roger A)
2.12M
2.46%
-6.42K
-0.30%
Jul 14, 2025
State Street Investment Management (US)
1.83M
2.13%
+42.99K
+2.40%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.68%
State Street SPDR S&P Pharmaceuticals ETF
2.33%
Virtus LifeSci Biotech Clinical Trials ETF
1.14%
Invesco Dorsey Wright Healthcare Momentum ETF
1.07%
First Trust Small Cap Growth AlphaDEX Fund
0.83%
iShares U.S. Pharmaceuticals ETF
0.61%
Federated Hermes MDT Small Cap Core ETF
0.41%
First Trust Small Cap Core Alphadex Fund
0.34%
iShares Micro-Cap ETF
0.3%
State Street SPDR S&P Kensho New Econ Comp ETF
0.27%
View more
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion2.68%
State Street SPDR S&P Pharmaceuticals ETF
Proportion2.33%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.14%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion1.07%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.83%
iShares U.S. Pharmaceuticals ETF
Proportion0.61%
Federated Hermes MDT Small Cap Core ETF
Proportion0.41%
First Trust Small Cap Core Alphadex Fund
Proportion0.34%
iShares Micro-Cap ETF
Proportion0.3%
State Street SPDR S&P Kensho New Econ Comp ETF
Proportion0.27%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Liquidia Corp?
The top five shareholders of Liquidia Corp are:
Farallon Capital Management, L.L.C. holds 6.83M shares, accounting for 7.94% of the total shares.
Caligan Partners, LP holds 8.12M shares, accounting for 9.43% of the total shares.
Manning (Paul B.) holds 6.16M shares, accounting for 7.21% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 4.26M shares, accounting for 4.95% of the total shares.
The Vanguard Group, Inc. holds 3.58M shares, accounting for 4.16% of the total shares.
Farallon Capital Management, L.L.C. holds 6.83M shares, accounting for 7.94% of the total shares.
Caligan Partners, LP holds 8.12M shares, accounting for 9.43% of the total shares.
Manning (Paul B.) holds 6.16M shares, accounting for 7.21% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 4.26M shares, accounting for 4.95% of the total shares.
The Vanguard Group, Inc. holds 3.58M shares, accounting for 4.16% of the total shares.
What are the top three shareholder types of Liquidia Corp?
The top three shareholder types of Liquidia Corp are:
Farallon Capital Management, L.L.C.
Caligan Partners, LP
Manning (Paul B.)
Farallon Capital Management, L.L.C.
Caligan Partners, LP
Manning (Paul B.)
How many institutions hold shares of Liquidia Corp (LQDA)?
As of 2025Q4, 372 institutions hold shares of Liquidia Corp, with a combined market value of approximately 63.78M, accounting for 73.31% of the total shares. Compared to 2025Q3, institutional shareholding has increased by 3.19%.
What is the biggest source of revenue for Liquidia Corp?
In FY2024, the -- business generated the highest revenue for Liquidia Corp, amounting to -- and accounting for --% of total revenue.
